Reality Check on Ulcerative Colitis
Market access for ulcerative colitis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 62% and 58% of the lives under commercial and health exchange formularies are covered with utilization management restrictions, respectively
- Class Trends: In April 2019, Highmark Inc. said it is targeting autoimmune diseases under a new outcomes-based contract with Takeda Pharmaceuticals U.S.A., Inc. for Entyvio (vedolizumab)
- Key Findings: Manufacturers with franchises across indications often hold contracting power and improved position, which is everything in this market
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.